DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Conditions

• Borderline-resectable Pancreatic Cancer

Eligibility Criteria

Sex

ALL

Age

19 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Point-of-care Portable Perfusion Phantom (P4) — DEVICE
  P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.

Study Details

The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast-enhanced magnetic resonance imaging, or DCE-MRI, for over 10 years. This technique has been globally used to calculate the blood flow of various tissues, including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor typically has low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy can result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, the investigators may be able to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and deciding whether to continue the therapy or try a different one.

Key Dates

Start date

Oct 10, 2024

Status verified

Feb 2025

Primary completion

Mar 31, 2029

Completion

Mar 31, 2029

Study Design

Enrollment

50 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Arms

• Experimental: borderline-resectable pancreatic cancer (BRPC)

Primary Outcome Measure

To measure the reproducibility of qDCE-MRI measurement of BRPC. [ Time Frame: 6 weeks +/- 2 weeks ]

Central Contacts

• Tamara Stein, MPH
  614-293-8315
  [email protected]

Locations (2)

Find similar trials in Indianapolis, IN